Voltron Therapeutics, Inc. Announces Positive Data from Animal Testing of Self-Assembling Vaccine in the Fight Against COVID-19

From globenewswire.com:

Voltron Therapeutics, Inc. today announced positive data from its second set of preclinical animal testing of its HaloVax™ Self-Assembling Vaccine (SAV) against COVID-19. This study investigated an updated construct, based on initial testing as well as recent scientific developments, in order to identify the best balance of immune responses for prevention of this pandemic pathogen. HaloVax is being developed in conjunction with Hoth Therapeutics, Inc (NASDAQ: HOTH).

Read full article: Voltron Therapeutics, Inc. Announces Positive Data from Animal Testing of Self-Assembling Vaccine in the Fight Against COVID-19

Voltron Therapeutics, Inc. Announces Positive Data from Animal Testing of Self-Assembling Vaccine in the Fight Against COVID-192021-03-30T21:53:13+00:00

Laidlaw Capital Markets is pleased to have acted as Co-Manager on the $25,000,000 Follow-On Offering for iCAD Inc.

The Team at Laidlaw Capital Markets is pleased to have acted as the Co-Manager on the $25,000,000 Follow-On Offering for iCAD, Inc. (ICAD). iCAD has been a partner for years now and we are excited for their continued success.

Click the link below for additional information:

iCAD Announces Closing of $25.0 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Laidlaw Capital Markets is pleased to have acted as Co-Manager on the $25,000,000 Follow-On Offering for iCAD Inc.2021-03-18T20:59:44+00:00

Laidlaw Venture Partners Portfolio Company, AerWave Medical, Inc., Closes $4,000,000 Series A Financing Round.

From globenewswire.com:

Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the successful closing of a $4 million Series A financing round for its portfolio company AerWave.

Click the link below for additional information:

AerWave Medical Closes Series A Financing

Laidlaw Venture Partners Portfolio Company, AerWave Medical, Inc., Closes $4,000,000 Series A Financing Round.2021-03-02T22:42:00+00:00

Laidlaw Capital Markets served as Financial Advisor on the $115,000,000 Follow-On Offering for EyePoint Pharmaceuticals

The Team at Laidlaw Capital Markets is pleased to have acted as Financial Advisor on the $115,000,000 Follow-On Offering, alongside Guggenheim and Cowen. This is the third transaction Laidlaw has been a part of with the company and we look forward to their continued success.

See full Press Release
Laidlaw Capital Markets served as Financial Advisor on the $115,000,000 Follow-On Offering for EyePoint Pharmaceuticals2021-02-10T14:34:06+00:00

Laidlaw Venture Partners Portfolio Company Voltron Therapeutics, Inc. Names Anthony Zook, Former CEO of AstraZeneca North America, Executive Chairman.

From globenewswire.com:

Voltron Therapeutics, Inc. today announced that it has appointed life science veteran Anthony Zook Executive Chairman of its Board of Directors.

As a global industry leader, Mr. Zook brings years of strategic experience to Voltron Therapeutics and is expected to be instrumental in the further development and eventual commercialization of its Self Assembling Vaccine (SAV) platform, and products such as the Covid-19 vaccine, HaloVax™ and cancer immunotherapy.

Read full article: Laidlaw Venture Partners Portfolio Company Voltron Therapeutics, Inc. Names Anthony Zook, Former CEO of AstraZeneca North America, Executive Chairman (globenewswire.com)

Laidlaw Venture Partners Portfolio Company Voltron Therapeutics, Inc. Names Anthony Zook, Former CEO of AstraZeneca North America, Executive Chairman.2021-03-03T16:59:11+00:00

Laidlaw served as Sole Book-Runner on the $14,375,000 Offering for Evoke Pharma (EVOK)

Laidlaw Capital Markets is pleased to have acted as the Sole Book-Runner on the $14,375,000 Follow-On Offering for Evoke Pharma (EVOK). Evoke has been a partner for years now and we are excited for their continued progress as a commercial stage company.

https://evokepharmainc.gcs-web.com/news-releases/news-release-details/evoke-pharma-announces-pricing-public-offering-common-stock-0

Laidlaw served as Sole Book-Runner on the $14,375,000 Offering for Evoke Pharma (EVOK)2021-03-03T16:56:06+00:00

Laidlaw Venture Partners portfolio company, Amesite (Nasdaq Ticker, AMST), CEO Ann Marie Sastry on Fox Business News today

From prnewswire.com:

Amesite Inc. (Nasdaq: AMST), an artificial intelligence software company providing online learning ecosystems for business, higher education, and K-12, announced today its CEO, Dr. Ann Marie Sastry, is scheduled to appear today on Fox Business Network’s CAVUTO Coast to Coast which airs weekdays at Noon ET.

Please click the link below for more information:

Amesite CEO Dr. Ann Marie Sastry Scheduled to Appear Today on Fox Business Network’s CAVUTO Coast to Coast (prnewswire.com)

Laidlaw Venture Partners portfolio company, Amesite (Nasdaq Ticker, AMST), CEO Ann Marie Sastry on Fox Business News today2021-03-02T22:35:17+00:00
Go to Top